dc.creator | Remón, Jordi | es |
dc.creator | Bernabé-Caro, Reyes | es |
dc.creator | Felip, E. | es |
dc.creator | González Larriba, J.L. | es |
dc.creator | Lázaro, M. | es |
dc.creator | Mielgo Rubio, X | es |
dc.creator | Sánchez, A. | es |
dc.creator | Sullivan, I. | es |
dc.creator | Massuti, B. | es |
dc.date.accessioned | 2022-10-03T14:00:57Z | |
dc.date.available | 2022-10-03T14:00:57Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Remón, J., Bernabé-Caro, R., Felip, E., González Larriba, J.L., Lázaro, M., Mielgo Rubio, X.,...,Massuti, B. (2022). SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021). Cinical and Translational Oncology, 24 (4), 635-645. https://10.1007/s12094-022-02788-w. | |
dc.identifier.issn | 1699-048X | es |
dc.identifier.issn | 1699-3055 | es |
dc.identifier.uri | https://hdl.handle.net/11441/137563 | |
dc.description.abstract | Thymic epithelial tumours (TET) represent a heterogeneous group of rare malignancies that include thymomas and thymic
carcinoma. Treatment of TET is based on the resectability of the tumour. If this is considered achievable upfront, surgical
resection is the cornerstone of treatment. Platinum-based chemotherapy is the standard regimen for advanced TET. Due
to the rarity of this disease, treatment decisions should be discussed in specifc multidisciplinary tumour boards, and there
are few prospective clinical studies with new strategies. However, several pathways involved in TET have been explored as
potential targets for new therapies in previously treated patients, such as multi-tyrosine kinase inhibitors with antiangiogenic
properties and immune checkpoint inhibitors (ICI). One third of patient with thymoma present an autoimmune disorders,
increasing the risk of immune-related adverse events and autoimmune fares under ICIs. In these guidelines, we summarize
the current evidence for the therapeutic approach in patients with TET and defne levels of evidence for these decisions | es |
dc.format | application/pdf | es |
dc.format.extent | 11 p. | es |
dc.language.iso | eng | es |
dc.publisher | SPRINGER | es |
dc.relation.ispartof | Cinical and Translational Oncology, 24 (4), 635-645. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Thymic epithelial tumours | es |
dc.subject | Chemotherapy | es |
dc.subject | Lenvatinib | es |
dc.subject | Nivolumab | es |
dc.subject | Multidisciplinary | es |
dc.title | SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021) | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://link.springer.com/article/10.1007/s12094-022-02788-w | es |
dc.identifier.doi | 10.1007/s12094-022-02788-w | es |
dc.journaltitle | Cinical and Translational Oncology | es |
dc.publication.volumen | 24 | es |
dc.publication.issue | 4 | es |
dc.publication.initialPage | 635 | es |
dc.publication.endPage | 645 | es |